Barr Pharmaceuticals Inc.: PharmaVitae Profile

Publication Date	December 2008
Publisher	Datamonitor
Product Type	Report
Pages	109
ISBN Number	not applicable
Product Code	DAT14041

Buy this product or for assistance call +44 20 7060 7474

PDF £3,425.00$5697 | €3833

FAX Order above formats by FAX

Summary

Introduction

This analysis examines the historical and forecast performance for Barr in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

Benchmark Barr's performance against key rivals in the prescription pharmaceutical sector
Assess the future commercial potential of Barr in light of its impending acquisition by Teva, due to be completed in late 2008/early 2009
Analyze Barr's leading position in the global market for generic oral contraceptive products

Content

CHAPTER 1 ABOUT THIS PROFILE
- Executive summary
- Quarterly news update
- Company introduction
- Company sales
- Company financials
- Key products and competitors
- Data sourcing
- Sales data
- Analyst consensus
CHAPTER 2 EXECUTIVE SUMMARY
- Key findings
- Prescription pharmaceutical sales performance, 2001-13
- Financial performance, 2001-13
- Barr: PharmaVitae forecasts at a glance
- Strategic insight
- Barriers to entry reduce the decline facing generic drugs
- M&A as the primary mechanism of generic company growth
- Teva will dictate strategic direction
- SWOT analysis
CHAPTER 3 QUARTERLY NEWS UPDATE
- Product developments
- Deals and alliances
- Product deals
- Technology deals
- M&A activity
- Company announcements
- Future product milestones
CHAPTER 4 COMPANY INTRODUCTION
- Key findings
- Background
- Key corporate developments
- M&A History
CHAPTER 5 COMPANY SALES
- Key findings
- Prescription pharmaceutical sales and growth rate analysis, 2001-13
- Product analysis
- Product analysis, 2001-07
- Product analysis, 2007-13
- Therapy area analysis
- Therapy area analysis, 2001-07
- Therapy area analysis, 2007-13
- Therapy area focus, 2001-13
- Geographic analysis
- Geographic analysis, 2001-07
- Geographic analysis, 2007-13
- Geographic focus, 2001-13
- Launch/core/expiry analysis
- Explanation of launch/core/expiry analysis
- Launch analysis, 2007-13
- Core analysis, 2007-13
- Expiry analysis, 2007-13
- Launch/core/expiry configuration, 2007-13
- Molecule type analysis
- Molecule type analysis, 2001-07
- Molecule type analysis, 2007-13
- Externalization analysis
- Externalization analysis, 2001-07
- Externalization analysis, 2007-13
CHAPTER 6 COMPANY FINANCIALS
- Key findings
- Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2001-07
- Financial statements, 2001-07
- Profit and loss account, 2001-07
- Balance sheet, 2001-07
- Operating costs and profit analysis
- Operating costs and profit analysis, 2001-07
- Operating cost ratio and profit margin analysis, 2001-07
- Operating cost ratio and profit margin analysis, 2007-13
- Operating costs and profit analysis, 2007-13
- Return on capital employed analysis
- Capital employed analysis, 2001-07
- Return on capital employed (RoCE) analysis, 2001-07
CHAPTER 7 KEY PRODUCTS AND COMPETITORS
- Key findings
- Overview
- Urology and gender-specific health
- Seasonale
- Seasonale becomes Barr's biggest branded OC
- Generic threat prompts Seasonique launch in 2006
- Generics launch in 2006 despite patent re-issue
- Ocella; generic Yasmin
- Central nervous system
- generic Adderall XR
CHAPTER 8 APPENDIX
- References
- Abbreviations
- Exchange rates
- Table 1: Barr - PharmaVitae forecasts at a glance
- Table 2: Barr key product developments, Q1-Q3 2008
- Table 3: Barr product deals and alliances, Q1-Q3 2008
- Table 4: Barr technology deals and alliances, Q1-Q3 2008
- Table 5: Barr M&A activity, Q1-Q3 2008
- Table 6: Barr company announcements, Q1-Q3 2008
- Table 7: Barr future product milestones, 2008-10
- Table 8: Barr product portfolio overview ($m), 2001-07
- Table 9: Barr product portfolio overview ($m), 2007-13
- Table 10: Barr product portfolio overview ($m), 2001-07
- Table 11: Barr product portfolio overview ($m), 2007-13
- Table 12: Barr portfolio overview by geographic region ($m), 2001-07
- Table 13: Barr portfolio overview by geographic region ($m), 2007-13
- Table 14: Barr launch portfolio overview ($m), 2007-13
- Table 15: Barr core portfolio overview ($m), 2007-13
- Table 16: Barr expiry portfolio overview ($m), 2007-13
- Table 17: Barr portfolio overview by molecule type ($m), 2001-07
- Table 18: Barr product portfolio overview by molecule type ($m), 2007-13
- Table 19: Barr product portfolio overview by source ($m), 2001-07
- Table 20: Barr product portfolio overview by source ($m), 2007-13
- Table 21: Total Barr sales by business unit ($m), 2001-07
- Table 22: Barr profit and loss account ($m), 2001-07
- Table 23: Barr balance sheet ($m), 2001-07
- Table 24: Barr operating revenue/cost analysis ($m), 2001-07
- Table 25: Barr operating cost ratio analysis (% of total revenues), 2001-07
- Table 26: Barr operating cost ratio analysis (% of total revenues), 2007-13
- Table 27: Barr operating revenue/cost analysis ($m), 2007-13
- Table 28: Barr capital employed ($m), 2001-07
- Table 29: Barr EBIT return on capital employed ($m), 2001-07
- Table 30: Barr EBIT pre-tax return/Capital employed driver analysis (%), 2001-07
- Table 31: Seasonale: overview
- Table 32: Seasonale: sales forecast ($m), 2007-13
- Table 33: Seasonique: sales forecast ($m), 2007-13
- Table 34: Ocella; generic Yasmin: overview
- Table 35: gen. Yasmin: sales forecast ($m), 2007-13
- Table 36: generic Adderall XR: overview
- Table 37: gen. Adderall XR: sales forecast ($m), 2007-13
- Table 38: Exchange rates, 2007
List of Figures
- Figure 1: Barr prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13
- Figure 2: Barr's financial performance ($m), 2001-13xx
- Figure 3: Illustrative branded and generic product lifecycles
- Figure 4: Growth strategies employed by Barr
- Figure 5: Barr prescription pharmaceutical sales ($m), 2001-13
- Figure 6: Barr SWOT analysis
- Figure 7: Barr's M&A history, 2001-06
- Figure 8: Barr prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13
- Figure 9: Barr key sales growth driver & resistors ($m), 2001-07
- Figure 10: Barr prescription pharmaceutical sales ($m), 2001-07
- Figure 11: Barr key sales growth drivers & resistors ($m), 2007-13
- Figure 12: Barr prescription pharmaceutical sales by therapy area ($m), 2001-13
- Figure 13: Barr prescription pharma sales by therapy area (% of total), 2001-13
- Figure 14: Barr prescription pharmaceutical sales by geographic region ($m), 2001-13
- Figure 15: Barr growth drivers and resistors by geographic region ($m), 2001-07
- Figure 16: Barr drivers and resistors by geographic region ($m), 2007-13
- Figure 17: Barr prescription pharmaceutical sales by geographic region (% of total), 2001-13
- Figure 18: Barr launch/core/expiry configuration ($m), 2007-13
- Figure 19: Barr prescription pharmaceutical sales by molecule type ($m), 2001-13
- Figure 20: Barr growth drivers and resistors by molecule type ($m), 2007-13
- Figure 21: Barr prescription pharmaceutical sales by source ($m), 2001-13
- Figure 22: Barr growth drivers and resistors by source ($m), 2001-07
- Figure 23: Barr growth drivers and resistors by source ($m), 2007-13
- Figure 24: Barr operating revenue/cost analysis ($m), 2001-13
- Figure 25: Barr operating cost ratio analysis (% of total revenues), 2001-13
- Figure 26: Barr return on capital employed, EBIT margin and capital turnover, 2001-07
- Figure 27: Return on capital employed formula